Traitomic raises €20m for non-GM trait development

Traitomic raises €20m for non-GM trait development

Traitomic has raised €20m to expand non-GM trait development activities. Its FIND-IT platform identifies genetic variants in crops and microorganisms, with customer validation still required before industrial adoption.


IN Brief:

  • Traitomic has secured €20m in Series A funding led by Sofinnova Partners.
  • The FIND-IT platform screens genetic variants rather than introducing targeted gene edits.
  • The company reports 116 traits delivered across 32 organisms, with customer testing required before many commercial applications.

Traitomic has secured €20m in Series A financing to extend its non-GM trait development platform into additional food, crop and industrial biotechnology applications. The Copenhagen company emerged from research at Carlsberg and uses large libraries of biological variation to identify plants or microorganisms with desired characteristics. Funding will support broader customer development work and international expansion, rather than the construction of a specific new food factory.

Sofinnova Partners led the round, with participation from the Export and Investment Fund of Denmark, Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures. It is Traitomic’s first external financing since its separation from Carlsberg, according to reporting published on 17 November. No allocation has been disclosed for individual laboratories, production facilities or territories. The company intends to broaden services that currently begin with the identification and recovery of useful genetic variants.

FIND-IT originated in the Carlsberg Research Laboratory’s work on barley for brewing. Rather than direct a molecular editing tool to change a selected gene, the system searches populations in which genetic variation already exists or has been generated through conventional mutagenesis methods. Researchers screen large numbers of plants or microbial cells for variants associated with a chosen characteristic and recover material carrying the change. Selecting such material differs technically from directly introducing an edit into the customer’s chosen strain or variety.

Traitomic organises the process around a biological library and its TraitTracker procedure. The company calls the screening stage Seeker and the extraction or recovery stage Selector, followed by validation and implementation with the customer. FIND-IT uses genetic screening to locate rare variants among large sample populations, but identifying a sequence difference alone does not prove a useful industrial result. The recovered crop or microorganism must be tested for the intended characteristic and for unwanted effects on growth, yield or process performance.

Carlsberg retains the underlying FIND-IT intellectual property and rights associated with brewing, while Traitomic holds an exclusive licence for specified applications outside that field. The arrangement provides a route for research developed around brewing raw materials to be applied to ingredients, seed development and industrial biotechnology. It does not mean Carlsberg has sold its brewery research rights or that all potential uses are available without contractual restrictions.

The business reports delivery of 116 customer-requested traits to 47 customers across 32 organisms. These figures describe identified or supplied traits, rather than 116 commercial products already being sold at scale. Traitomic’s reported work spans crops and microorganisms, but a recipient may still need to complete breeding, strain optimisation, industrial validation, regulatory review or commercial testing before the new characteristic is used in production.

Enzymes and fermentation-derived ingredients offer potential uses for microbial variants that change substrate consumption, product yield or tolerance to particular process conditions. In these applications, laboratory screening has to be followed by measurements in the customer’s actual process, where bioreactor conditions, nutrient supply and downstream recovery affect performance. For plants, desirable changes may concern raw material quality, stress tolerance or characteristics that influence extraction and processing. The longer breeding cycles of many crops can extend the interval between trait identification and industrial use.

Traitomic says it can sometimes identify and supply individual traits within four to eight weeks when a suitable screening platform is already established. The claim concerns discovery and delivery; it does not include every subsequent trial or approval needed to commercialise a food ingredient. Chief executive Gustav Hambraeus has said some microbial applications have entered products, while many plant traits remain within customer development programmes. Neither outcome is captured adequately by the number of traits delivered alone.

The absence of direct gene editing may simplify some customers’ market-access decisions, but treatment depends on how the variation was generated, the organism, the finished product and the jurisdiction. Conventional mutagenesis, breeding and gene editing do not have uniform regulatory treatment globally. The company’s proposition therefore rests on measurable trait performance, screening speed and customers’ ability to integrate the supplied material, rather than on a general claim that all non-GM routes are automatically exempt from scrutiny.

Traitomic identifies the US and Australia as priority markets for expansion and aims to become more involved in downstream development with customers. Working earlier with a customer’s own microbial strain or crop variety could reduce the work needed to transfer an identified trait into a commercial programme, though that benefit has to be demonstrated project by project. The €20m round finances that next phase, with adoption in validated food and industrial processes providing a firmer measure of progress than the number of discoveries alone.


Stories for you


  • Circana finds €20.5bn in European CPG launch sales

    Circana finds €20.5bn in European CPG launch sales

    European consumer goods launches generated €20.5bn in measured retail sales. Circana reports fewer introductions but stronger incremental value, with frozen foods, chilled products, and confectionery among the notable food categories.


  • AkzoNobel urges integrated approach to food packaging

    AkzoNobel urges integrated approach to food packaging

    AkzoNobel calls for packaging decisions to consider complete production systems. Food protection, coating compatibility, reduced material use, and recycling infrastructure must be evaluated together rather than by material alone.